GoKawiilMerck-Moderna Personalized Melanoma Vaccine Shows 82% Recurrence-Free Rate at Two Years
Merck and Moderna released full results from a trial of their personalized mRNA melanoma vaccine earlier than planned, after details apparently leaked. The companies reported that 82% of patients who received the vaccine alongside Keytruda remained cancer-free two years later.
GoKawiil's interpretation of the reporting above, not reported fact.
The early release suggests the companies wanted to control the narrative once data began circulating outside official channels, though neither firm has stated that motive publicly. Despite the strong efficacy numbers, investors sent both stocks lower, which could reflect skepticism about trial design, costs of personalized vaccines, or broader market conditions rather than doubts about the science itself.
- 82% of trial participants remained cancer-free two years after receiving the personalized vaccine plus Keytruda.
- Data was released ahead of schedule following an apparent leak of trial results.
- Despite positive clinical results, Merck and Moderna shares fell on the news.
Source: gizmodo.com, 2026-10-23
Published there as: “These Melanoma Patients Got a Vaccine Made for Their Own Tumors. 2 Years Later, 82% Are Still Cancer-Free”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.